Monthly ART Injections Top Pills for HIV Patients With Adherence Problems
Long-acting cabotegravir/rilpivirine (Cabenuva; CAB/RPV-LA) appeared superior to daily oral antiretroviral therapy (ART) in maintaining viral load suppression for people living with HIV who have trouble adhering to oral ART, according to an interim analysis of a phase III trial. At 52 weeks, numerically fewer patients assigned to monthly injections of CAB/RPV-LA experienced regimen failure — […]
Long-Acting Injectable Comparable to Oral ART for HIV in Sub-Saharan Africa
DENVER — Long-acting cabotegravir/rilpivirine (Cabenuva) injectable therapy resulted in similarly high levels of viral suppression to oral antiretroviral therapy (ART) in African patients with HIV, a phase IIIb randomized, open-label trial showed. At 48 weeks, 96.9% of participants receiving cabotegravir/rilpivirine had a viral load of less than 50 copies/mL compared with 97.3% of those receiving […]